Low-dose aspirin in the primary prevention of cancer. The women's health study: A randomized controlled trial

JAMA

Volumn 294, Issue 1, 2005, Pages 47-55

  Cook, Nancy R ^a,b   Lee, I Min ^a,b   Gaziano, J Michael ^a,c   Gordon, David ^a   Ridker, Paul M ^a,b   Manson, JoAnn E ^a,b   Hennekens, Charles H ^d,e   Buring, Julie E ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BETA CAROTENE; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; AGED; ANAMNESIS; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL EXAMINATION; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HEALTH; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LEUKEMIA; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OBSERVATION; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; THYROID CANCER; TIME SERIES ANALYSIS; UNITED STATES; UTERUS CANCER; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; INCIDENCE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM; RISK FACTOR;

ASPIRIN; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS; RISK FACTORS;

EID: 21444450527     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.1.47     Document Type: Article

References (40)

1. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst. 1998;90:1529-1536.
2. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst. 1998;90:1609-1620.
3. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer. 2003;3:28.
4. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12:88-93.
5. Asano TK, McLeod RS. Nonsteroidal antiinflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum. 2004;47:665-673.
6. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer. 2001;84:1188-1192.
7. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-1218.
8. Thun MJ. Beyond willow bark: aspirin in the prevention of chronic disease. Epidemiology. 2000;11:371-374.
9. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291:2433-2440.
10. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313-316.
11. Gann PH, Manson JAE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85:1220-1224.
12. Sturmer T, Glynn RJ, Lee IM, Manson JAE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up from the Physicians' Health Study. Ann Intern Med. 1998;128:713-720.
13. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
14. Lee IM, Cook NR, Manson JAE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst. 1999;91:2102-2106.
15. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med. 2000;9:19-27.
16. Cox DR. Regression models and life tables (with discussion). J Roy Stat Soc [Ser B]. 1972;34:187-220.
17. Anderson JR, ed. Muir's Textbook of Pathology. 12th ed. London, England: Edward Arnold; 1985.
18. Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer. 2004;91:525-529.
19. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003;63:6096-6101.
20. Baron JA, Cole BF, Sandler RS, et al. A randomized trial to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
21. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC Trial. Gastroenterology. 2003;125:328-336.
22. Sandler RS, Halabie S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.
23. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241-246.
24. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609-614.
25. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138-146.
26. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989;299:1247-1250.
27. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE. Aspirin and lung cancer in women. Br J Cancer. 2002;87:49-53.
28. Holick CN, Michaud DS, Leitzman MF, Willett WC, Giovannucci EL. Aspirin use and lung cancer in men. Br J Cancer. 2003;89:1705-1708.
29. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep. 2002;9:693-695.
30. Muscat JE, Chen SQ, Richie JP Jr, et al. Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer. 2003;97:1732-1736.
31. Patrono C, Coller B, Dalen J, et al. Platelet-active drugs: the relationship among dose, effectiveness, and side effects. Chest. 2001;119:39S-63S.
32. Ridker PM, Hennekens CH, Tofler GH, Lipinska I, Buring JE. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk. 1996;3:209-212.
33. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90:455-460.
34. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology. 2000;11:376-381.
35. Chan AT, Giovannucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med. 2004;140:157-166.
36. Tangrea JA, Albert PS, Lanza E, et al. Nonsteroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control. 2003;14:403-411.
37. 2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:447-453.
38. 2 levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 2002;11:275-279.
39. Baron JA. Epidemiology of non-steroidal antiinflammatory drugs and cancer. In: Dannenberg AJ, DuBois RN, eds. COX-2. Vol 37. Basel, Switzerland: Karger; 2003:1-24.
40. Cook NR, Hebert PR, Manson JAE, Buring JE, Hennekens CH. Self-selected aspirin use post-trial and subsequent cardiovascular disease and mortality in the Physicians' Health Study. Arch Intern Med. 2000;160:921-928.